Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference

Seaport Therapeutics (SPTX) will present at the Stifel 2026 Healthcare Conference on November 10, 2026, at 4:00 p.m. EST.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON--(BUSINESS WIRE)-- Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced its participation in the Stifel 2026 Healthcare Conference, being held November 10-12, 2026, at the Lotte New York Palace Hotel in New York City.

Members of the management team will present on Tuesday, November 10, at 4:00 p.m. EST. The Company will also participate in one-on-one investor meetings during the conference.

A live webcast will be available on the Investors section of the Company’s website at https://investors.seaporttx.com/news-events/events. An archived replay will be available following the presentation.

About Seaport Therapeutics

Seaport Therapeutics (Nasdaq: SPTX) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through its differentiated approach, the Company identifies clinically validated mechanisms with established efficacy and safety which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. Seaport applies its proprietary Glyph™ platform to overcome those limitations and invent innovative oral therapies. With an experienced team of industry leaders, Seaport has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. Seaport aims to develop novel, leading treatment options that will make a significant impact for patients and their families. For more information, please visit www.seaporttx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261028709124/en/

Seaport Therapeutics  
Media Contact:  
Shannon Costello  
Vice President, Communications  
publicrelations@seaporttx.com  

Investor Contact:  
Adam Bero, Ph.D.  
Vice President, Head of Investor Relations  
ir@seaporttx.com  

Source: Seaport Therapeutics, Inc.

Key Terms

first-pass metabolism medical

First-pass metabolism is the process by which a drug taken by mouth is partly broken down in the gut wall and liver before it reaches the bloodstream, so less active medicine is available to the body. For investors, it matters because a high first-pass effect can force higher doses, different formulations or alternative delivery methods, increasing development cost, regulatory complexity and the commercial attractiveness of a drug—think of it as a filter that removes part of the product before it reaches customers.

bioavailability medical

Bioavailability is the measure of how much and how quickly a substance, such as a medication or nutrient, enters the bloodstream and becomes available for use by the body. For investors, it matters because it influences how effectively a product works and how quickly results are seen, which can impact a company's success and the potential value of related investments. Think of it like how much of a medicine actually reaches your bloodstream after taking it—that determines how well it can do its job.